Cholecystokinin-dopamine coexistence: electrophysiological actions corresponding to cholecystokinin receptor subtype
- PMID: 3760947
- PMCID: PMC6568787
- DOI: 10.1523/JNEUROSCI.06-10-03039.1986
Cholecystokinin-dopamine coexistence: electrophysiological actions corresponding to cholecystokinin receptor subtype
Abstract
Cholecystokinin (CCK)-like peptides when administered intravenously produce 2 distinct actions on the single-unit activity of mesencephalic dopamine (DA) neurons in the rat: an excitatory action and a potentiation of the inhibitory effects of DA agonists. The ability of several CCK fragments that have been shown to bind selectively to the peripheral and/or the central CCK-binding sites were examined for their ability to induce either excitation or a potentiation of DA. Only sulfated CCK-8 was able to induce excitation of mesencephalic DA neurons, but both sulfated and unsulfated CCK-8, as well as CCK-4, potentiated the inhibitory effects of the DA agonist apomorphine (APO). CCK-3 failed to potentiate APO-induced inhibition. Both of these effects appeared to be confined to cell bodies in regions of the ventral tegmental area and substantia nigra, zona compacta that have been reported to contain both DA and CCK. Thus, CCK-like peptides that have been shown to bind to the high-affinity CCK binding site in brain potentiated the effects of DA. In contrast, the ability of CCK-like peptides to induce neuronal excitation corresponds with their affinity for the peripheral-type CCK binding site.
Similar articles
-
Effects of the CCK-A receptor antagonist CR 1409 on the activity of rat midbrain dopamine neurons.Peptides. 1991 Mar-Apr;12(2):339-43. doi: 10.1016/0196-9781(91)90023-i. Peptides. 1991. PMID: 2067986
-
Electrophysiological effects of cholecystokinin: central dopaminergic systems.Prog Clin Biol Res. 1985;192:95-103. Prog Clin Biol Res. 1985. PMID: 4080721
-
Electrophysiological effects of diphenylpyrazolidinone cholecystokinin-B and cholecystokinin-A antagonists on midbrain dopamine neurons.J Pharmacol Exp Ther. 1993 Jan;264(1):480-8. J Pharmacol Exp Ther. 1993. PMID: 8423546
-
Substance P and cholecystokinin regulate neurochemical responses to cocaine and methamphetamine in the striatum.Life Sci. 2003 Jun 27;73(6):727-39. doi: 10.1016/s0024-3205(03)00393-x. Life Sci. 2003. PMID: 12801594 Review.
-
Cholecystokinin peptides, dopamine and schizophrenia--a review.Prog Neuropsychopharmacol Biol Psychiatry. 1985;9(5-6):515-24. doi: 10.1016/0278-5846(85)90011-9. Prog Neuropsychopharmacol Biol Psychiatry. 1985. PMID: 2868491 Review.
Cited by
-
Differential involvement of CCK-A and CCK-B receptors in the regulation of locomotor activity in the mouse.Psychopharmacology (Berl). 1991;105(3):393-9. doi: 10.1007/BF02244435. Psychopharmacology (Berl). 1991. PMID: 1798834
-
Cell-Cell Communication Alterations via Intercellular Signaling Pathways in Substantia Nigra of Parkinson's Disease.Front Aging Neurosci. 2022 Feb 25;14:828457. doi: 10.3389/fnagi.2022.828457. eCollection 2022. Front Aging Neurosci. 2022. PMID: 35283752 Free PMC article.
-
Electrical stimulation of the prefrontal cortex increases cholecystokinin, glutamate, and dopamine release in the nucleus accumbens: an in vivo microdialysis study in freely moving rats.J Neurosci. 1998 Aug 15;18(16):6492-500. doi: 10.1523/JNEUROSCI.18-16-06492.1998. J Neurosci. 1998. PMID: 9698337 Free PMC article.
-
Neurobehavioural effects of SR 27897, a selective cholecystokinin type A (CCK-A) receptor antagonist.Naunyn Schmiedebergs Arch Pharmacol. 1993 Jul;348(1):102-7. doi: 10.1007/BF00168544. Naunyn Schmiedebergs Arch Pharmacol. 1993. PMID: 8397341
-
Modelling anxiety in humans for drug development.Curr Neuropharmacol. 2007 Mar;5(1):65-72. doi: 10.2174/157015907780077114. Curr Neuropharmacol. 2007. PMID: 18615150 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources